Shares of Tissue Regenix Group Plc (TRX.L) climbed around 18 percent in the morning trading in London after the British regenerative medical devices company announced that it has launched DermaPure, its decellularised dermis product, in the US.
Tissue Regenix's partner Community Tissue Services or CTS will begin shipping product to customers next week.
DermaPure is initially being targeted at acute care patients with diabetic foot ulcers. The company noted that the commercial launch of the DermaPure dermis allograft will now allow Tissue Regenix to target a market worth $1.4 billion a year for wound healing devices and equipment.
Tissue Regenix said its DermaPure works by taking human donor skin and removing the DNA and cells, using the patented dCELL process to leave a natural biological scaffold that can be placed in the wound to aid natural healing by attracting the patient's own cells to the wound area.
Tissue Regenix noted that its patented decellularisation or dCELL technology removes DNA and other cellular material from animal and human tissue leaving an acellular.
In addition to the launch of DermaPure, the company announced that it has continued to expand its distribution network around the country and currently has a network of over 60 reps that covers 80 percent of the US.
In addition, Tissue Regenix has signed an exclusive government supplier partnership with TASSMA for the distribution of DermaPure. The partnership with TASSMA will allow Tissue Regenix to immediately target the Department of Veteran's Affairs Healthcare System and the numerous branches of the US military, the company noted.
Greg Bila, President of Tissue Regenix Wound Care Inc. said, "Commercial production and distribution of the DermaPure is a significant step forward for Tissue Regenix. This paves the way for the development of other human tissue based medical treatments."
In London, Tissue Regenix shares are currently trading at 24.15 pence, up 3.65 pence or 17.80 percent.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org